Integrin signalling adaptors: Not only figurants in the cancer story

Nature Reviews Cancer

Volumn 10, Issue 12, 2010, Pages 858-870

  Cabodi, Sara ^a   Del Pilar Camacho Leal, Maria ^a   Di Stefano, Paola ^a   Defilippi, Paola ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTOR PROTEIN; CRK ASSOCIATED SUBSTRATE PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GROWTH FACTOR RECEPTOR; INTEGRIN; INTEGRIN LINKED KINASE; P140 CAS ASSOCIATED PROTEIN; PARVIN; PEPTIDES AND PROTEINS; PHOSPHOPROTEIN; PROTEIN NEDD9; TAMOXIFEN; UNCLASSIFIED DRUG;

APOPTOSIS; BREAST CANCER; CANCER INVASION; CARCINOGENESIS; CELL MIGRATION; CELL PROLIFERATION; CELL TRANSFORMATION; COLON CANCER; COMPLEX FORMATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; EXTRACELLULAR MATRIX; GENE OVEREXPRESSION; HUMAN; NEURAL STEM CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; TUMOR GROWTH;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADAPTOR PROTEINS, VESICULAR TRANSPORT; ANIMALS; APOPTOSIS; CELL MOVEMENT; HUMANS; INTEGRINS; NEOPLASM INVASIVENESS; NEOPLASMS; PHOSPHOPROTEINS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-CRK; RECEPTOR, ERBB-2; TRANSFORMING GROWTH FACTOR BETA;

EID: 78649474761     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc2967     Document Type: Review

References (159)

1. Desgrosellier, J. S. & Cheresh, D. A. Integrins in cancer: biological implications and therapeutic opportunities. Nature Rev. Cancer 10, 9-22 (2010).
2. Cabodi, S. et al. Integrins and signal transduction. Adv. Exp. Med. Biol. 674, 43-54 (2010).
3. Tikhmyanova, N., Little, J. L. & Golemis, E. A. CAS proteins in normal and pathological cell growth control. Cell. Mol. Life Sci. 67, 1025-1048 (2009).
4. Defilippi, P., Di Stefano, P. & Cabodi, S. p130Cas: a versatile scaffold in signaling networks. Trends Cell Biol. 16, 257-263 (2006).
5. Birge, R. B., Kalodimos, C., Inagaki, F. & Tanaka, S. Crk and CrkL adaptor proteins: networks for physiological and pathological signaling. Cell Commun. Signal. 7, 13 (2009).
6. Wickstrom, S. A., Lange, A., Montanez, E. & Fassler, R. The ILK/PINCH/parvin complex: the kinase is dead, long live the pseudokinase! EMBO J. 29, 281-291 (2009).
7. Singh, M. K. et al. A novel Cas family member, HEPL, regulates FAK and cell spreading. Mol. Biol. Cell 19, 1627-1636 (2008).
8. Ishino, M., Ohba, T., Sasaki, H. & Sasaki, T. Molecular cloning of a cDNA encoding a phosphoprotein, Efs, which contains a Src homology 3 domain and associates with Fyn. Oncogene 11, 2331-2338 (1995).
9. Honda, H. et al. Cardiovascular anomaly, impaired actin bundling and resistance to Src-induced transformation in mice lacking p130Cas. Nature Genet. 19, 361-365 (1998).
10. Ambrogio, C. et al. p130Cas mediates the transforming properties of the anaplastic lymphoma kinase. Blood 106, 3907-3916 (2005).
11. Cabodi, S. et al. p130Cas is an essential transducer element in ErbB2 transformation. FASEB J. 10, 3796-3808 (2010).
12. Pylayeva, Y. et al. Ras- and PI3K-dependent breast tumorigenesis in mice and humans requires focal adhesion kinase signaling. J. Clin. Invest. 11 9, 252-266 (2009).
13. Cabodi, S. et al. p130Cas as a new regulator of mammary epithelial cell proliferation, survival, and HER2-neu oncogene-dependent breast tumorigenesis. Cancer Res. 66, 4672-4680 (2006).
14. Tornillo, G. et al. p130Cas promotes invasiveness of three dimensional ErbB2-transformed mammary acinar structures by enhanced activation of mTOR/ p70S6K and Rac1. Euro. J. Cell Biol. 18 Oct 2010 (doi:10.1016/j.ejcb.2010.09. 002).
15. van der Flier, S. et al. BCAR1/p130Cas expression in untreated and acquired tamoxifen-resistant human breast carcinomas. Int. J. Cancer 89, 465-468 (2000).
16. van der Flier, S. et al. Immunohistochemical study of the BCAR1/p130Cas protein in non-malignant and malignant human breast tissue. Int. J. Biol. Markers 16, 172-178 (2001).
17. Dorssers, L. C. et al. The prognostic value of BCAR1 in patients with primary breast cancer. Clin. Cancer Res. 10, 6194-6202 (2004).
18. Chin, L. Modeling malignant melanoma in mice: pathogenesis and maintenance. Oncogene 18, 5304-5310 (1999).
19. Kim, M. et al. Comparative oncogenomics identifies NEDD9 as a melanoma metastasis gene. Cell 125, 1269-1281 (2006).
20. Lucas, J. T., Salimath, B. P., Slomiany, M. G. & Rosenzweig, S. A. Regulation of invasive behavior by vascular endothelial growth factor is HEF1-dependent. Oncogene 29, 4449-4459 (2010).
21. Izumchenko, E. et al. NEDD9 promotes oncogenic signaling in mammary tumor development. Cancer Res. 69, 7198-7206 (2009).
22. Matsuda, M. et al. Tw o species of human CRK cDNA encode proteins with distinct biological activities. Mol. Cell. Biol. 12, 3482-3489 (1992).
23. ten Hoeve, J., Morris, C., Heisterkamp, N. & Groffen, J. Isolation and chromosomal localization of CRKL, a human crk-like gene. Oncogene 8, 2469-2474 (1993).
24. Miller, C. T. et al. Increased C-CRK proto-oncogene expression is associated with an aggressive phenotype in lung adenocarcinomas. Oncogene 22, 7950-7957 (2003).
25. Nishihara, H. et al. Molecular and immunohistochemical analysis of signaling adaptor protein Crk in human cancers. Cancer Lett. 180, 55-61 (2002).
26. Takino, T. et al. CrkI adapter protein modulates cell migration and invasion in glioblastoma. Cancer Res. 63, 2335-2337 (2003).
27. Wang, L. et al. Signaling adaptor protein Crk is indispensable for malignant feature of glioblastoma cell line KMG4. Biochem. Biophys. Res. Commun. 362, 976-981 (2007).
28. Fathers, K. E. et al. CrkII transgene induces atypical mammary gland development and tumorigenesis. Am. J. Pathol. 176, 446-460 (2010).
29. Eke, I., Hehlgans, S. & Cordes, N. There's something about ILK. Int. J. Radiat. Biol. 85, 929-936 (2009).
30. McDonald, P. C., Fielding, A. B. & Dedhar, S. Integrin-linked kinase-essential roles in physiology and cancer biology. J. Cell Sci. 121, 3121-3132 (2008).
31. Hannigan, G., Troussard, A. A. & Dedhar, S. Integrin-linked kinase: a cancer therapeutic target unique among its ILK. Nature Rev. Cancer 5, 51-63 (2005).
32. Haase, M. et al. Expression of integrin-linked kinase is increased in differentiated cells. J. Histochem. Cytochem. 56, 819-829 (2008).
33. White, D. E., Cardiff, R. D., Dedhar, S. & Muller, W. J. Mammary epithelial-specific expression of the integrin-linked kinase (ILK) results in the induction of mammary gland hyperplasias and tumors in transgenic mice. Oncogene 20, 7064-7072 (2001). This article provides the first direct demonstration of a potential oncogenic role for ILK.
34. Pontier, S. M. et al. Integrin-linked kinase has a critical role in ErbB2 mammary tumor progression: implications for human breast cancer. Oncogene 29, 3374-3385 (2010).
35. Oloumi, A. et al. Cooperative signaling between Wnt1 and integrin-linked kinase induces accelerated breast tumor development. Breast Cancer Res. 12, R38 (2010).
36. Mongroo, P. S. et al. β-parvin inhibits integrin-linked kinase signaling and is downregulated in breast cancer. Oncogene 23, 8959-8970 (2004).
37. Wang-Rodriguez, J., Dreilinger, A. D., Alsharabi, G. M. & Rearden, A. The signaling adapter protein PINCH is up-regulated in the stroma of common cancers, notably at invasive edges. Cancer 95, 1387-1395 (2002).
38. Gao, J., Arbman, G., Rearden, A. & Sun, X. F. Stromal staining for PINCH is an independent prognostic indicator in colorectal cancer. Neoplasia 6, 796-801 (2004).
39. Damiano, L. et al. p140Cap dual regulation of E-cadherin/EGFR cross-talk and Ras signalling in tumour cell scatter and proliferation. Oncogene 29, 3677-3690 (2010).
40. Di Stefano, P. et al. p140Cap protein suppresses tumour cell properties, regulating Csk and Src kinase activity. EMBO J. 26, 2843-2855 (2007).
41. Di Stefano, P. et al. P130Cas-associated protein (p140Cap) as a new tyrosine-phosphorylated protein involved in cell spreading. Mol. Biol. Cell 15, 787-800 (2004).
42. Chin, L. S., Nugent, R. D., Raynor, M. C., Vavalle, J. P. & Li, L. SNIP, a novel SNAP-25-interacting protein implicated in regulated exocytosis. J. Biol. Chem. 275, 1191-1200 (2000).
43. Semba, K. et al. A novel murine gene, Sickle tail, linked to the Danforth's short tail locus, is required for normal development of the intervertebral disc. Genetics 172, 445-456 (2006).
44. Karasugi, T. et al. Association of the tag SNPs in the human SKT gene (KIAA1217) with lumbar disc herniation. J. Bone Miner. Res. 24, 1537-1543 (2009).
45. Ito, H. et al. Characterization of a multidomain adaptor protein, p140Cap, as part of a pre-synaptic complex. J. Neurochem. 107, 161-172 (2008).
46. DeGiorgis, J. A. et al. Phosphoproteomic analysis of synaptosomes from human cerebral cortex. J. Proteome Res. 4, 306-315 (2005).
47. Collins, M. O. et al. Proteomic analysis of in vivo phosphorylated synaptic proteins. J. Biol. Chem. 280, 5972-5982 (2005).
48. Kennedy, S. et al. SNIP/p140Cap mRNA expression is an unfavourable prognostic factor in breast cancer and is not expressed in normal breast tissue. Br. J. Cancer 98, 1641-1645 (2008).
49. Katoh, M. Evolutionary recombination hotspot around GSDML-GSDM locus is closely linked to the oncogenomic recombination hotspot around the PPP1R1B-ERBB2-GRB7 amplicon. Int. J. Oncol. 24, 757-763 (2004).
50. Ruest, P. J., Shin, N. Y., Polte, T. R., Zhang, X. & Hanks, S. K. Mechanisms of CAS substrate domain tyrosine phosphorylation by FAK and Src. Mol. Cell. Biol. 21, 7641-7652 (2001).
51. Heasman, S. J. & Ridley, A. J. Mammalian Rho GTPases: new insights into their functions from in vivo studies. Nature Rev. Mol. Cell Biol. 9, 690-701 (2008).
52. Soderling, S. H. Grab your partner with both hands: cytoskeletal remodeling by Arp2/3 signaling. Sci. Signal 2, pe5 (2009).
53. Petrie, R. J., Doyle, A. D. & Yamada, K. M. Random versus directionally persistent cell migration. Nature Rev. Mol. Cell Biol. 10, 538-549 (2009).
54. Kobashigawa, Y. et al. Structural basis for the transforming activity of human cancer-related signaling adaptor protein CRK. Nature Struct. Mol. Biol. 14, 503-510 (2007).
55. Holcomb, M., Rufini, A., Barila, D. & Klemke, R. L. Deregulation of proteasome function induces Abl-mediated cell death by uncoupling p130CAS and c-CrkII. J. Biol. Chem. 281, 2430-2440 (2006).
56. Janssen, H. & Marynen, P. Interaction partners for human ZNF384/CIZ/NMP4-zyxin as a mediator for p130CAS signaling? Exp. Cell Res. 312, 1194-1204 (2006).
57. Pratt, S. J. et al. The LIM protein Ajuba influences p130Cas localization and Rac1 activity during cell migration. J. Cell Biol. 168, 813-824 (2005).
58. Yi, J. et al. Members of the Zyxin family of LIM proteins interact with members of the p130Cas family of signal transducers. J. Biol. Chem. 277, 9580-9589 (2002).
59. Nakamoto, T. et al. CIZ, a zinc finger protein that interacts with p130(cas) and activates the expression of matrix metalloproteinases. Mol. Cell. Biol. 20, 1649-1658 (2000).
60. Brabek, J. et al. Crk-associated substrate tyrosine phosphorylation sites are critical for invasion and metastasis of SRC-transformed cells. Mol. Cancer Res. 3, 307-315 (2005).
61. Vultur, A. et al. SKI-606 (bosutinib), a novel Src kinase inhibitor, suppresses migration and invasion of human breast cancer cells. Mol. Cancer Ther. 7, 1185-1194 (2008).
62. Yu, H., Mouw, J. K. & Weaver, V. M. Forcing form and function: biomechanical regulation of tumor evolution. Trends Cell Biol. 24 Sep 2010 (doi:10.1016/j. tcb.2010.08.015).
63. Moore, S. W., Roca-Cusachs, P. & Sheetz, M. P. Stretchy proteins on stretchy substrates: the important elements of integrin-mediated rigidity sensing. Dev. Cell 19, 194-206 (2010).
64. Sawada, Y. et al. Force sensing by mechanical extension of the Src family kinase substrate p130Cas. Cell 127, 1015-1026 (2006).
65. Kostic, A. & Sheetz, M. P. Fibronectin rigidity response through Fyn and p130Cas recruitment to the leading edge. Mol. Biol. Cell 17, 2684-2695 (2006).
66. Sanz-Moreno, V. et al. Rac activation and inactivation control plasticity of tumor cell movement. Cell 135, 510-523 (2008).
67. Natarajan, M. et al. HEF1 is a necessary and specific downstream effector of FAK that promotes the migration of glioblastoma cells. Oncogene 25, 1721-1732 (2006).
68. Simpson, K. J. et al. Identification of genes that regulate epithelial cell migration using an siRNA screening approach. Nature Cell Biol. 10, 1027-1038 (2008).
69. Massague, J. TGFβ in Cancer. Cell 134, 215-230 (2008).
70. Thiery, J. P., Acloque, H., Huang, R. Y. & Nieto, M. A. Epithelial-mesenchymal transitions in development and disease. Cell 139, 871-890 (2009).
71. Zhang, H. et al. Transforming growth factor-β1-induced apoptosis is blocked by β1-integrin-mediated mitogen-activated protein kinase activation in human hepatoma cells. Cancer Sci. 95, 878-886 (2004).
72. Kim, W. et al. The integrin-coupled signaling adaptor p130Cas suppresses Smad3 function in transforming growth factor-β signaling. Mol. Biol. Cell 19, 2135-2146 (2008).
73. Wendt, M. K., Smith, J. A. & Schiemann, W. P. p130Cas is required for mammary tumor growth and transforming growth factor-β-mediated metastasis through regulation of Smad2/3 activity. J. Biol. Chem. 284, 34145-34156 (2009).
74. Giampieri, S. et al. Localized and reversible TGFβ signalling switches breast cancer cells from cohesive to single cell motility. Nature Cell Biol. 11, 1287-1296 (2009).
75. Thiery, J. P. & Sleeman, J. P. Complex networks orchestrate epithelial-mesenchymal transitions. Nature Rev. Mol. Cell Biol. 7, 131-142 (2006).
76. 2-terminal kinase 1 and up-regulating N-cadherin expression. Cancer Res. 66, 11745-11753 (2006).
77. Shintani, Y., Wheelock, M. J. & Johnson, K. R. Phosphoinositide-3 kinase-Rac1-c-Jun NH2-terminal kinase signaling mediates collagen I-induced cell scattering and up-regulation of N-cadherin expression in mouse mammary epithelial cells. Mol. Biol. Cell 17, 2963-2975 (2006).
78. Shintani, Y. et al. Collagen I-mediated up-regulation of N-cadherin requires cooperative signals from integrins and discoidin domain receptor 1. J. Cell Biol. 180, 1277-1289 (2008).
79. Bhattacharya, S., Guo, H., Ray, R. M. & Johnson, L. R. Basic helix-loop-helix protein E47-mediated p21Waf1/Cip1 gene expression regulates apoptosis of intestinal epithelial cells. Biochem. J. 407, 243-254 (2007).
80. Kim, W., Kook, S., Kim, D. J., Teodorof, C. & Song W. K. The 31-kDa caspase-generated cleavage product of p130cas functions as a transcriptional repressor of E2A in apoptotic cells. J. Biol. Chem. 279, 8333-8342 (2004).
81. Law, S. F., O'Neill, G. M., Fashena, S. J., Einarson M. B. & Golemis, E. A. The docking protein HEF1 is an apoptotic mediator at focal adhesion sites. Mol. Cell. Biol. 20, 5184-5195 (2000).
82. Daouti, S. et al. A selective phosphatase of regenerating liver phosphatase inhibitor suppresses tumor cell anchorage-independent growth by a novel mechanism involving p130Cas cleavage. Cancer Res. 68, 1162-1169 (2008).
83. Achiwa, H. & Lazo, J. S. PRL-1 tyrosine phosphatase regulates c-Src levels, adherence, and invasion in human lung cancer cells. Cancer Res. 67, 643-650 (2007).
84. Wendt, M. K., Drury, L. J., Vongsa, R. A. & Dwinell, M. B. Constitutive CXCL12 expression induces anoikis in colorectal carcinoma cells. Gastroenterology 135, 508-517 (2008).
85. Gasparini, G., Longo, R., Sarmiento, R. & Morabito, A. Inhibitors of cyclo-oxygenase 2: a new class of anticancer agents? Lancet Oncol. 4, 605-615 (2003).
86. Casanova, I. et al. Celecoxib induces anoikis in human colon carcinoma cells associated with the deregulation of focal adhesions and nuclear translocation of p130Cas. Int. J. Cancer 118, 2381-2389 (2006).
87. Casanova, I. et al. A celecoxib derivative inhibits focal adhesion signaling and induces caspase-8-dependent apoptosis in human acute myeloid leukemia cells. Int. J. Cancer 123, 217-226 (2008).
88. Sakai, R., Nakamoto, T., Ozawa, K., Aizawa, S. & Hirai, H. Characterization of the kinase activity essential for tyrosine phosphorylation of p130Cas in fibroblasts. Oncogene 14, 1419-1426 (1997).
89. Iwahara, T., Akagi, T., Fujitsuka, Y. & Hanafusa, H. CrkII regulates focal adhesion kinase activation by making a complex with Crk-associated substrate, p130Cas. Proc. Natl Acad. Sci. USA 101, 17693-17698 (2004).
90. Akagi, T., Shishido, T., Murata, K. & Hanafusa, H. v-Crk activates the phosphoinositide 3-kinase/AKT pathway in transformation. Proc. Natl Acad. Sci. USA 97, 7290-7295 (2000).
91. Watanabe, T. et al. Crk adaptor protein-induced phosphorylation of Gab1 on tyrosine 307 via Src is important for organization of focal adhesions and enhanced cell migration. Cell Res. 19, 638-650 (2009).
92. Watanabe, T. et al. Adaptor molecule Crk is required for sustained phosphorylation of Grb2-associated binder 1 and hepatocyte growth factor-induced cell motility of human synovial sarcoma cell lines. Mol. Cancer Res. 4, 499-510 (2006).
93. Crawford, M. et al. MicroRNA-126 inhibits invasion in non-small cell lung carcinoma cell lines. Biochem. Biophys. Res. Commun. 373, 607-612 (2008).
94. Legate, K. R., Montanez, E., Kudlacek, O. & Fassler, R. ILK, PINCH and parvin: the tIPP of integrin signalling. Nature Rev. Mol. Cell Biol. 7, 20-31 (2006).
95. Attwell, S., Mills, J., Troussard, A., Wu, C. & Dedhar, S. Integration of cell attachment, cytoskeletal localization, and signaling by integrin-linked kinase (ILK), CH-ILKBP, and the tumor suppressor PTEN. Mol. Biol. Cell 14, 4813-4825 (2003).
96. Yamaji, S. et al. A novel integrin-linked kinase-binding protein, affixin, is involved in the early stage of cell-substrate interaction. J. Cell Biol. 153, 1251-1264 (2001).
97. Lange, A. et al. Integrin-linked kinase is an adaptor with essential functions during mouse development. Nature 461, 1002-1006 (2009).
98. 2+-dependent protein kinase that regulates glycogen synthase kinase-3(3 (GSK-3(3) phosphorylation. PLoS ONE 5, e12356 (2010).
99. Fukuda, K., Gupta, S., Chen, K., Wu, C. & Qin, J. The pseudoactive site of ILK is essential for its binding to a-Parvin and localization to focal adhesions. Mol. Cell 36, 819-830 (2009).
100. Somasiri, A., Howarth, A., Goswami, D., Dedhar, S. & Roskelley, C. D. Overexpression of the integrin-linked kinase mesenchymally transforms mammary epithelial cells. J. Cell Sci. 114, 1125-1136 (2001).
101. Filipenko, N. R., Attwell, S., Roskelley, C. & Dedhar, S. Integrin-linked kinase activity regulates Rac- and Cdc42-mediated actin cytoskeleton reorganization via ct-PIX. Oncogene 24, 5837-5849 (2005).
102. Troussard, A. A. et al. The integrin linked kinase (ILK) induces an invasive phenotype via AP-1 transcription factor-dependent upregulation of matrix metalloproteinase 9 (MMP-9). Oncogene 19, 5444-5452 (2000).
103. Fielding, A. B., Dobreva, I., McDonald, P. C, Foster, L. J. & Dedhar, S. Integrin-linked kinase localizes to the centrosome and regulates mitotic spindle organization. J. Cell Biol. 180, 681-689 (2008). These data demonstrate an unexpected function for ILK in the organization of centrosomal protein complexes during mitotic spindle assembly and DNA segregation.
104. Fielding, A. B., Lim, S., Montgomery, K., Dobreva, I. & Dedhar, S. A critical role of integrin-linked kinase, ch-TOG and TACC3 in centrosome clustering in cancer cells. Oncogene. 13 Sep 2010 (doi:10.1038/ onc.2010.431).
105. Durbin, A. D., Hannigan, G. E. & Malkin, D. Oncogenic ILK, tumor suppression and all that JNK. Cell Cycle 8, 4060-4066 (2009).
106. Troussard, A. A. et al. Preferential dependence of breast cancer cells versus normal cells on integrin-linked kinase for protein kinase B/Akt activation and cell survival. Cancer Res. 66, 393-403 (2006).
107. Durbin, A. D. et al. JNK 1 determines the oncogenic or tumor-suppressive activity of the integrin-linked kinase in human rhabdomyosarcoma. J. Clin. Invest. 119, 1558-1570 (2009).
108. Wexler, L. H., Crist, W. M. & Helman, L. J. in In Principles and Practice of Pediatric Oncology (eds Pizzo, P. A. & Poplack, D. G.) 939-971 (Lippincott Williams & Wilkins., Philadelphia, Pennsylvania, 2002).
109. Fukuda, T, Chen, K., Shi, X. & Wu, C. PINCH-1 is an obligate partner of integrin-linked kinase (ILK) functioning in cell shape modulation, motility, and survival. J. Biol. Chem. 278, 51324-51333 (2003).
110. Johnstone, C. N. et al. Parvin-p inhibits breast cancer tumorigenicity and promotes CDK9-mediated peroxisome proliferator-activated receptor y1 phosphorylation. Mol. Cell. Biol. 28, 687-704 (2008).
111. Castellvi-Bel, S. et al. Evaluation of PARVG located on 22q 13 as a candidate tumor suppressor gene for colorectal and breast cancer. Cancer Genet. Cytogenet. 144, 80-82 (2003).
112. Chen, K. et al. PINCH-1 regulates the ERK-Bim pathway and contributes to apoptosis resistance in cancer cells. J. Biol. Chem. 283, 2508-2517 (2008).
113. Liang, X. et al. Pinch 1 is required for normal development of cranial and cardiac neural crest-derived structures. Circ. Res. 100, 527-535 (2007).
114. Latour, S. & Veillette, A. Proximal protein tyrosine kinases in immunoreceptor signaling. Curr. Opin. Immunol. 13, 299-306 (2001).
115. Perrais, M., Chen, X., Perez-Moreno, M. & Gumbiner, B. M. E-cadherin homophilic ligation inhibits cell growth and epidermal growth factor receptor signaling independently of other cell interactions. Mol. Biol. Cell 18, 2013-2025 (2007).
116. Qian, X., Karpova, T., Sheppard, A. M., McNally, J. & Lowy, D. R. E-cadherin-mediated adhesion inhibits ligand-dependent activation of diverse receptor tyrosine kinases. EMBO J. 23, 1739-1748 (2004).
117. Takahashi, K. & Suzuki, K. Density-dependent inhibition of growth involves prevention of EGF receptor activation by E-cadherin-mediated cell-cell adhesion. Exp. Cell Res. 226, 214-222 (1996).
118. Prescott, J. et al. Androgen receptor-mediated repression of novel target genes. Prostate 67, 1371-1383 (2007).
119. Jaworski, J. et al. Dynamic microtubules regulate dendritic spine morphology and synaptic plasticity. Neuron 61, 85-100 (2009).
120. Cabodi, S. et al. p130Cas interacts with estrogen receptor α and modulates non-genomic estrogen signaling in breast cancer cells. J. Cell Sci. 11 7, 1603-1611 (2004).
121. Brinkman, A., van der Flier, S., Kok, E. M. & Dorssers, L. C. BCAR1, a human homologue of the adapter protein p130Cas, and antiestrogen resistance in breast cancer cells. J. Natl Cancer Inst. 92, 112-120 (2000).
122. van Agthoven, T. et al. Identification of BCAR3 by a random search for genes involved in antiestrogen resistance of human breast cancer cells. EMBO J. 17, 2799-2808 (1998).
123. Dorssers, L. C. et al. Tamoxifen resistance in breast cancer: elucidating mechanisms. Drugs 61, 1721-1733 (2001).
124. Gotoh, T., Cai, D., Tian, X., Feig, L. A. & Lerner, A. p130Cas regulates the activity of AND-34, a novel Ral, Rap1, and R-Ras guanine nucleotide exchange factor. J. Biol. Chem. 275, 30118-30123 (2000).
125. Makkinje, A. et al. AND-34/BCAR3 regulates adhesion-dependent p130Cas serine phosphorylation and breast cancer cell growth pattern. Cell. Signal. 21, 1423-1435 (2009).
126. Brinkman, A. et al. The substrate domain of BCAR1 is essential for anti-estrogen-resistant proliferation of human breast cancer cells. Breast Cancer Res. Treat 120, 401-408 (2009).
127. Ta, H. Q., Thomas, K. S., Schrecengost, R. S. & Bouton, A. H. A novel association between p130Cas and resistance to the chemotherapeutic drug adriamycin in human breast cancer cells. Cancer Res. 68, 8796-804 (2008).
128. Thao le, B. et al. Cas-L was overexpressed in imatinib-resistant gastrointestinal stromal tumor cells. Cancer Biol. Ther. 8, 683-688 (2009).
129. Edwards, L. A. et al. Inhibition of ILK in PTEN-mutant human glioblastomas inhibits PKB/Akt activation, induces apoptosis, and delays tumor growth. Oncogene 24, 3596-3605 (2005).
130. Wong, R. P., Ng, P., Dedhar, S. & Li, G. The role of integrin-linked kinase in melanoma cell migration, invasion, and tumor growth. Mol. Cancer Ther. 6, 1692-1700 (2007).
131. Edwards, L. A. et al. Suppression of VEGF secretion and changes in glioblastoma multiforme microenvironment by inhibition of integrin-linked kinase (ILK). Mol. Cancer Ther. 7, 59-70 (2008).
132. Liu, J. et al. Integrin-linked kinase inhibitor KP-392 demonstrates clinical benefits in an orthotopic human non-small cell lung cancer model. J. Thorac. Oncol. 1, 771-779 (2006).
133. Yau, C. Y., Wheeler, J. J., Sutton, K. L. & Hedley, D. W. Inhibition of integrin-linked kinase by a selective small molecule inhibitor, QLT0254, inhibits the PI3K/PKB/mTOR, Stat3, and FKHR pathways and tumor growth, and enhances gemcitabine-induced apoptosis in human orthotopic primary pancreatic cancer xenografts. Cancer Res. 65, 1497-1504 (2005).
134. Wisniewska, M. et al. The 1.1 A resolution crystal structure of the p130cas SH3 domain and ramifications for ligand selectivity. J. Mol. Biol. 347, 1005-1014 (2005).
135. Assoian, R. K. & Klein, E. A. Growth control by intracellular tension and extracellular stiffness. Trends Cell Biol. 18, 347-352 (2008).
136. Streuli, C. H. & Akhtar, N. Signal co-operation between integrins and other receptor systems. Biochem. J. 418, 491-506 (2009).
137. Desgrosellier, J. S. et al. An integrin αvβ3-c-Src oncogenic unit promotes anchorage-independence and tumor progression. Nature Med. 15, 1163-1169 (2009).
138. Brakebusch, C. & Fassler, R. β1 integrin function in vivo: adhesion, migration and more. Cancer Metastasis Rev. 24, 403-411 (2005).
139. Christofori, G. New signals from the invasive front. Nature 441, 444-450 (2006).
140. Nam, J. M., Chung, Y., Hsu, H. C. & Park, C. C. β1 integrin targeting to enhance radiation therapy. Int. J. Radiat. Biol. 85, 923-928 (2009).
141. Defilippi, P. et al. β1 Integrin and IL-3R coordinately regulate STAT5 activation and anchorage-dependent proliferation. J. Cell Biol. 168, 1099-1108 (2005).
142. Uberti, B., Dentelli, P., Rosso, A., Defilippi, P., & Brizzi, M. F. Inhibition of β1 Integrin and IL-3 β common subunit interaction hinders tumor angiogenesis. Oncogene 30 Aug 2010 (doi:10.1038/ onc.2010.384).
143. Caswell, P. T., Vadrevu, S. & Norman, J. C. Integrins: masters and slaves of endocytic transport. Nature Rev. Mol. Cell Biol. 10, 843-853 (2009).
144. Muller, P. A. et al. Mutant p53 drives invasion by promoting integrin recycling. Cell 139, 1327-1341 (2009).
145. Salgia, R. et al. p130CAS forms a signaling complex with the adapter protein CRKL in hematopoietic cells transformed by the BCR/ABL oncogene. J. Biol. Chem. 271, 25198-25203 (1996).
146. Iwata, S. et al. HTLV-I Ta x induces and associates with Crk-associated substrate lymphocyte type (Cas-L). Oncogene 24, 1262-1271 (2005).
147. Bravou, V., Klironomos, G., Papadaki, E., Taraviras, S. & Varakis, J. ILK over-expression in human colon cancer progression correlates with activation of β-catenin, down-regulation of E-cadherin and activation of the Akt-FKHR pathway. J. Pathol. 208, 91-99 (2006).
148. Dai, D. L. et al. Increased expression of integrin-linked kinase is correlated with melanoma progression and poor patient survival. Clin. Cancer Res. 9, 4409-4414 (2003).
149. Takanami, I. Increased expression of integrin-linked kinase is associated with shorter survival in non-small cell lung cancer. BMC Cancer 5, 1 (2005).
150. Sawai, H. et al. Integrin-linked kinase activity is associated with interleukin-1 α-induced progressive behavior of pancreatic cancer and poor patient survival. Oncogene 25, 3237-3246 (2006).
151. Graff, J. R. et al. Integrin-linked kinase expression increases with prostate tumor grade. Clin. Cancer Res. 7, 1987-1991 (2001).
152. Huang, H. C. et al. Thymosin β4 triggers an epithelial-mesenchymal transition in colorectal carcinoma by upregulating integrin-linked kinase. Oncogene 26, 2781-2790 (2007).
153. Ahmed, N. et al. Integrin-linked kinase expression increases with ovarian tumour grade and is sustained by peritoneal tumour fluid. J. Pathol. 201, 229-237 (2003).
154. Watzka, S. B. et al. Reactivity of integrin-linked kinase in human mesothelial cell proliferation. Interact. Cardiovasc. Thorac. Surg. 7, 107-110 (2008).
155. Chung, D. H. et al. ILK (β1-integrin-linked protein kinase): a novel immunohistochemical marker for Ewing's sarcoma and primitive neuroectodermal tumour. Virchows Arch. 433, 113-117 (1998).
156. Zhu, Z. et al. PINCH expression and its significance in esophageal squamous cell carcinoma. Dis. Markers 25, 75-80 (2008).
157. Wang, M. W. et al. Expression of PINCH protein in gliomas and its clinicopathological significance. Oncology 72, 343-346 (2007).
158. Zhang, J. T. et al. Up-regulation of PINCH in the stroma of oral squamous cell carcinoma predicts nodal metastasis. Oncol. Rep. 14, 1519-1522 (2005).
159. Zhao, Z. R. et al. Particularly interesting new cysteine-histidine rich protein expression in colorectal adenocarcinomas. World J. Gastroenterol. 12, 298-301 (2006).